Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis.
Marina Kleopatra BozikiAlexandros PechlivanisChristina VirgiliouChristos BakirtzisStyliani Aggeliki SintilaEleni KarafoulidouEvangelia KesidouPaschalis TheotokisIoannis NikolaidisGeorgios A TheodoridisHelen G GikaNikolaos GrigoriadisPublished in: International journal of molecular sciences (2022)
Biomarker research across the health-to-disease continuum is being increasingly applied. We applied blood-based metabolomics in order to identify patient clusters with a first demyelinating episode, and explored the prognostic potential of the method by thoroughly characterizing each cluster in terms of clinical, laboratory and MRI markers of established prognostic potential for Multiple Sclerosis (MS). Recruitment consisted of 11 patients with Clinically Isolated Syndrome (CIS), 37 patients with a first demyelinating episode in the context of Relapsing-Remitting MS (RRMS) and 11 control participants. Blood-based metabolomics and hierarchical clustering analysis (HCL) were applied. Constructed OPLS-DA models illustrated a discrimination between patients with CIS and the controls ( p = 0.0014), as well as between patients with RRMS and the controls ( p = 1 × 10 -5 ). Hierarchical clustering analysis (HCL) for patients with RRMS identified three clusters. RRMS-patients-cluster-3 exhibited higher mean cell numbers in the Cerebro-spinal Fluid (CSF) compared to patients with CIS (18.17 ± 6.3 vs. 1.09 ± 0.41, p = 0.004). Mean glucose CSF/serum ratio and infratentorial lesion burden significantly differed across CIS- and HCL-derived RRMS-patient clusters (F = 14.95, p < 0.001 and F = 6.087, p = 0.002, respectively), mainly due to increased mean values for patients with RRMS-cluster-3. HCL discriminated a cluster of patients with a first demyelinating episode in the context of RRMS with increased disability, laboratory findings linked with increased pathology burden and MRI markers of poor prognosis.
Keyphrases
- multiple sclerosis
- poor prognosis
- long non coding rna
- mass spectrometry
- contrast enhanced
- white matter
- magnetic resonance imaging
- single cell
- case report
- public health
- newly diagnosed
- mental health
- ms ms
- diffusion weighted imaging
- chronic kidney disease
- computed tomography
- stem cells
- magnetic resonance
- metabolic syndrome
- type diabetes
- disease activity
- weight loss
- risk assessment
- health information
- risk factors
- climate change
- patient reported